WS #11714
PepsiCo beats revenue estimates but North America food revenue declines 2%; stock -2% premarket; company cuts snack prices but not enough to drive growth. Ionis and AstraZeneca's Phase 3 eplontersen misses primary endpoint in ATTR-CM; secondary measures and safety favorable.
PepsiCo Q2 Earnings & Consumer Pressure
PepsiCo beats revenue estimates but North America food revenue declines 2%; stock -2% premarket; company cuts snack prices but not enough to drive growth.
Ionis and AstraZeneca's Phase 3 eplontersen misses primary endpoint in ATTR-CM; secondary measures and safety favorable.